{"title":"肌醇与二甲双胍对多囊卵巢综合征妇女的疗效比较","authors":"Nurmeen Latif, Seema Rajar, Mehreen Yousuf, Sadaf Imtiaz, Sidrah Abbas, Zara Jamali","doi":"10.37185/lns.1.1.486","DOIUrl":null,"url":null,"abstract":"Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic ovary syndrome.Study Design: Cross-sectional study.Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the normalization of menstrual cycles and the achievement of ovulation.Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively. The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively. Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with p-value=0.001.Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of polycystic ovary syndrome.How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z. Comparison of Efficacy Between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. Life and Science. 2024; 5(1): 48-53. doi: http://doi.org/10.37185/LnS.1.1.486","PeriodicalId":516717,"journal":{"name":"Life and Science","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome\",\"authors\":\"Nurmeen Latif, Seema Rajar, Mehreen Yousuf, Sadaf Imtiaz, Sidrah Abbas, Zara Jamali\",\"doi\":\"10.37185/lns.1.1.486\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic ovary syndrome.Study Design: Cross-sectional study.Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the normalization of menstrual cycles and the achievement of ovulation.Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively. The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively. Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with p-value=0.001.Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of polycystic ovary syndrome.How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z. Comparison of Efficacy Between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. Life and Science. 2024; 5(1): 48-53. doi: http://doi.org/10.37185/LnS.1.1.486\",\"PeriodicalId\":516717,\"journal\":{\"name\":\"Life and Science\",\"volume\":\"23 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Life and Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37185/lns.1.1.486\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life and Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37185/lns.1.1.486","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
研究目的比较肌醇与二甲双胍治疗多囊卵巢综合征妇女的效果:横断面研究:研究地点和时间:研究在鲁思博士(Dr. Ruth. K.M. Pfau th.K.M. Pfau th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.Methods:所有到医院就诊的符合条件的患者均被纳入。A组包括接受肌醇治疗的女性(35人),B组包括接受二甲双胍治疗的女性(35人)。肌醇组女性每天服用两次肌醇,每次1克;二甲双胍组女性每天服用两次二甲双胍,每次500毫克。每两个月进行一次定期随访,六个月后对疗效进行评估。疗效根据月经周期是否正常和是否排卵进行评估:肌醇组和二甲双胍组的平均年龄分别为(23.92±3.70)岁和(23.68±4.23)岁。肌醇组和二甲双胍组的平均体重分别为(59.23±2.07)和(61.79±5.92)。值得注意的是,肌醇组和二甲双胍组的有效率分别为 68.57% 和 20%,P 值=0.001:在治疗多囊卵巢综合征方面,肌醇明显优于二甲双胍:Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z.肌醇与二甲双胍对多囊卵巢综合征妇女的疗效比较》。生命与科学2024; 5(1):48-53. doi: http://doi.org/10.37185/LnS.1.1.486
Comparison of Efficacy between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome
Objective: To compare the effectiveness of myo-inositol versus metformin in treating women with polycystic ovary syndrome.Study Design: Cross-sectional study.Place and Duration of Study: The study was carried out at the Department of Gynae Unit II, Dr. Ruth. K.M. Pfau th th Civil Hospital Karachi, Pakistan from 7 February 2019 to 6 August 2019.Methods: All eligible patients who visited the hospital were enrolled. The group-Aincluded females who received myo-inositol (n=35), whereas the group-B included females who received metformin (n=35). Females in the myo-inositol group were administered 1 gram of myo-inositol twice daily, while those in the metformin group were administered 500 mg of metformin twice daily. Regular follow-up visits were scheduled every two months, and the efficacy of the treatment was assessed after six months. Efficacy was evaluated in terms of the normalization of menstrual cycles and the achievement of ovulation.Results: The mean age in the myo-inositol and metformin groups was 23.92±3.70 and 23.68±4.23, respectively. The mean weight in the myoinositol and metformin groups was 59.23±2.07 and 61.79±5.92, respectively. Notably, the efficacy rates for the myo-inositol and metformin groups were 68.57% and 20%, respectively with p-value=0.001.Conclusion: Myo-inositol was found to demonstrate significant superiority over metformin in the treatment of polycystic ovary syndrome.How to cite this: Latif N, Rajar S, Yousuf M, Imtiaz S, Abbas S, Jamali Z. Comparison of Efficacy Between Myo-Inositol versus Metformin in Women with Polycystic Ovary Syndrome. Life and Science. 2024; 5(1): 48-53. doi: http://doi.org/10.37185/LnS.1.1.486